CD274 and breast cancer: In fact, depletion of MDSCs in a murine BC model, following treatment with ibrutinib, an irreversible inhibitor of Bruton's tyrosine kinase, significantly improved the efficacy of immune-based therapies, including that of anti-PD-L1 therapy [76].